VEGF-Based Delivery of Boron Therapeutics

Award Information
Agency:
Department of Energy
Branch
n/a
Amount:
$0.00
Award Year:
2003
Program:
SBIR
Phase:
Phase I
Contract:
DE-FG02-03ER83774
Award Id:
61850
Agency Tracking Number:
70733S02-II
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
705 North Mountain Road, Newington, CT, 06111
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
Joseph Backer
(860) 953-1164
jbacker@sibtech.com
Business Contact:
Joseph Backer
(860) 953-1164
jbacker@sibtech.com
Research Institute:
n/a
Abstract
70733S02-II Because the growth of primary tumor and metastatic lesions beyond a few millimeters requires formation of new blood vessels (angiogenesis), the targeted delivery of cytotoxic drugs to growing tumor blood vessels may form the basis for a highly selective cancer therapy. Particularly attractive are two-step therapies that initially deliver relatively non-toxic ¿prodrugs¿ that are subsequently activated at the sites of angiogenesis. This project will develop a two-step therapy that relies on the targeted delivery of non-toxic boron-10 (10B) to the tumor vasculature. When the site is irradiated with low-energy neutrons, they will be captured by the 10B atoms, which will undergo nuclear fission and yield high-energy products that destroy cells. Phase I constructed and tested in vitro assembled nanovehicles for boron-10 delivery. These nanovehicles carried a high capacity polymeric carrier for boron-10 that allows a ¿loading¿ of 1120 boron atoms per every targeted molecule. The assembled nanovehicles were shown to be non-toxic, capable of binding to cellular receptors of vascular endothelial growth factor, and internalized by targeted cells. Phase II will test assembled targeted nanovehicles in animal tumor models. Novel, high capacity assembled nanovehicles will be constructed that combine imaging and therapeutic capabilities. Commercial Applications and Other Benefits as described by awardee: Targeted boron-10 therapeutics may provide an attractive alternative to highly toxic systemic chemotherapy and radiotherapy of cancer.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government